📊 HCIL Key Takeaways
Is HCIL a Good Investment? Thesis Analysis
Company demonstrates positive net income ($1.0M) but exhibits critical cash flow deterioration with negative operating cash flow (-$641.3K) and free cash flow (-$1.5M), indicating severe earnings quality concerns. Acute liquidity crisis with current ratio 0.85x and dangerously low cash reserves ($551.8K) against $22.2M liabilities creates existential solvency risk.
Why Buy HCIL? Key Strengths
- Positive net income and acceptable 10% operating margin demonstrate underlying business profitability
- Conservative leverage with 0.16x debt-to-equity ratio provides some balance sheet cushion
- Minimal debt service burden with 1118x interest coverage ratio
HCIL Investment Risks to Consider
- Severe cash flow deterioration: negative operating cash flow and negative $1.5M free cash flow indicate earnings are not converting to cash
- Critical liquidity crisis: current ratio 0.85x and quick ratio 0.84x both below 1.0x with only $551.8K cash against $22.2M liabilities
- Extremely poor capital efficiency with ROE of only 2.4% and ROA of 1.5%, suggesting capital is underdeployed
- Small $11.3M revenue base limits financial flexibility and ability to absorb shocks
Key Metrics to Watch
- Operating cash flow trajectory and path to positive cash generation
- Cash position and liquidity ratios - must return to safe levels above 1.0x
- Free cash flow and monthly cash burn rate given precarious cash balance
HCIL Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
HCIL Profitability Ratios
HCIL vs Healthcare Sector
How Hongchang International Co., Ltd compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is HCIL Overvalued or Undervalued?
Based on fundamental analysis, Hongchang International Co., Ltd has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
HCIL Balance Sheet & Liquidity
HCIL 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Hongchang International Co., Ltd's revenue has grown significantly by 1,187% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.00 indicates the company is currently unprofitable.
HCIL Growth Metrics (YoY)
HCIL Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2026 | $2.8M | $304.3K | $0.00 |
| Q2 2026 | $2.8M | -$44.8K | $0.00 |
| Q1 2026 | $2.0M | -$21.7K | $0.00 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
HCIL Capital Allocation
HCIL SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Hongchang International Co., Ltd (CIK: 0001086303)
📋 Recent SEC Filings
❓ Frequently Asked Questions about HCIL
What is the AI rating for HCIL?
Hongchang International Co., Ltd (HCIL) has an AI rating of SELL with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are HCIL's key strengths?
Claude: Positive net income and acceptable 10% operating margin demonstrate underlying business profitability. Conservative leverage with 0.16x debt-to-equity ratio provides some balance sheet cushion.
What are the risks of investing in HCIL?
Claude: Severe cash flow deterioration: negative operating cash flow and negative $1.5M free cash flow indicate earnings are not converting to cash. Critical liquidity crisis: current ratio 0.85x and quick ratio 0.84x both below 1.0x with only $551.8K cash against $22.2M liabilities.
What is HCIL's revenue and growth?
Hongchang International Co., Ltd reported revenue of $11.3M.
Does HCIL pay dividends?
Hongchang International Co., Ltd does not currently pay dividends.
Where can I find HCIL SEC filings?
Official SEC filings for Hongchang International Co., Ltd (CIK: 0001086303) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is HCIL's EPS?
Hongchang International Co., Ltd has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is HCIL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Hongchang International Co., Ltd has a SELL rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is HCIL stock overvalued or undervalued?
Valuation metrics for HCIL: ROE of 2.4% (sector avg: 15%), net margin of 8.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy HCIL stock in 2026?
Our dual AI analysis gives Hongchang International Co., Ltd a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is HCIL's free cash flow?
Hongchang International Co., Ltd's operating cash flow is $-641.3K, with capital expenditures of $856.9K. FCF margin is -13.2%.
How does HCIL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 8.8% (avg: 12%), ROE 2.4% (avg: 15%), current ratio 0.85 (avg: 2).